Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) were up 11.6% during trading on Wednesday. The company traded as high as $9.25 and last traded at $9.3870. Approximately 1,157,035 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 3,201,408 shares. The stock had previously closed at $8.41.
Wall Street Analyst Weigh In
CAPR has been the topic of a number of recent research reports. Maxim Group downgraded Capricor Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, July 30th. HC Wainwright cut Capricor Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday, July 27th. Cantor Fitzgerald raised shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Friday, August 14th. Piper Sandler upgraded shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, September 1st. Finally, Ladenburg Thalmann & Co. Inc. lowered shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $30.09.
Get Our Latest Stock Report on Capricor Therapeutics
Capricor Therapeutics Price Performance
The stock has a market cap of $530.12 million, a P/E ratio of -3.43 and a beta of 0.80. The stock's 50 day simple moving average is $8.07 and its two-hundred day simple moving average is $19.72.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.29). As a group, analysts forecast that Capricor Therapeutics, Inc. will post -2.39 earnings per share for the current fiscal year.
Institutional Trading of Capricor Therapeutics
Hedge funds have recently made changes to their positions in the business. Algert Global LLC lifted its position in Capricor Therapeutics by 158.7% during the third quarter. Algert Global LLC now owns 79,200 shares of the biotechnology company's stock worth $750,000 after purchasing an additional 48,590 shares during the period. RA Capital Management L.P. raised its position in shares of Capricor Therapeutics by 99.9% in the 3rd quarter. RA Capital Management L.P. now owns 3,014,183 shares of the biotechnology company's stock valued at $28,544,000 after buying an additional 1,506,339 shares in the last quarter. Entropy Technologies LP acquired a new position in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $343,000. Jump Financial LLC lifted its holdings in shares of Capricor Therapeutics by 1,984.9% during the 3rd quarter. Jump Financial LLC now owns 480,286 shares of the biotechnology company's stock worth $4,548,000 after acquiring an additional 457,250 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Capricor Therapeutics by 21.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company's stock worth $164,000 after acquiring an additional 3,036 shares during the period. 21.68% of the stock is owned by institutional investors and hedge funds.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company's leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.